The full potential of genetic medicine is limited by the lack of safe and effective in vivo delivery technologies for many tissues and cell types. Current gene therapies face challenges in achieving cell-specific targeting, efficient delivery of diverse therapeutic cargoes, and minimizing off-target effects and immunogenicity. This restricts the application of precision medicines to a wider range of previously undruggable diseases.

nChroma Bio is developing both best-in-class therapeutic cargoes, specifically epigenetic editors, and targeted in vivo delivery technologies to overcome the limitations of current gene therapies. The company's DLVR particles are engineered for tissue-specific delivery of multiple macromolecules, including ribonucleoproteins (RNPs) for gene editing. These modular, non-viral vehicles are designed for efficient in vivo editing with programmable cell-specific targeting. nChroma Bio's approach aims to expand the reach of precision medicines by enabling a modality-agnostic arsenal of genetic medicines.

Epigenetic editors with the potential for one-time, lifelong cures without altering the DNA sequence

High potency epigenetic editors at clinically relevant doses for gene silencing, activation, and multiplexed gene regulation

Reversible gene regulation capabilities

DLVR particles for efficient delivery of multiple macromolecules, including RNPs

Programmable DLVR particles for cell-specific targeting

Proprietary library of human envelopes with novel tropism for DLVR particles

In vitro validated humanized DLVR particles

The primary target audience includes researchers and pharmaceutical companies focused on developing gene therapies, particularly for chronic diseases with unmet needs, such as chronic hepatitis B and hepatitis D.